Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2‑UDP glucuronosyltransferase 1A metabolic axis activation

Hao,Qian; Wang,Min; Sun,Nuan‑Xin; Zhu,Cheng; Lin,Ying‑Min; Li,Cui; Liu,Fang; Zhu,Wen‑Wen

doi:10.3892/or.2020.7495

Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2‑UDP glucuronosyltransferase 1A metabolic axis activation

Authors:
- Qian Hao
- Min Wang
- Nuan‑Xin Sun
- Cheng Zhu
- Ying‑Min Lin
- Cui Li
- Fang Liu
- Wen‑Wen Zhu
View Affiliations

Affiliations: Department of Geriatric Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Jiangxi Medical School, Nanchang University, Nanchang, Jiangxi 330031, P.R. China, Department of General Practice, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Gastroenterology, Taian City Central Hospital, Taian, Shandong 271000, P.R. China
Published online on: February 10, 2020 https://doi.org/10.3892/or.2020.7495
Pages: 1067-1080
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long pre‑cancerous state of colorectal cancer (CRC) provides an opportunity to prevent the occurrence and development of CRC. The detoxification of CRC food‑borne carcinogenic heterocyclic amines is highly dependent on UDP glucuronosyltransferase 1A (UGT1A)‑mediated glucuronidation. Sulforaphane (SFN), a phytochemical, possesses antioxidant, anti‑inflammatory and anticarcinogenic effects on the prevention of CRC. Previous studies revealed that SFN upregulates the expression of UGT1A. The aim of the present study was to investigate the regulatory mechanism of SFN‑induced UGT1A upregulation and provide novel understanding on the basic research and chemoprevention of CRC. In the present study, the viability and proliferation of CRC cells (HT‑29 and SW480) treated with SFN were assessed by MTT, colony formation and EdU assays. Flow cytometry was used to detect the cell cycle arrest and apoptosis of cells treated with different concentrations of SFN. The motility of cells was determined by wound healing and Transwell assays. Nuclear factor, erythroid 2 like 2 (Nrf2) short hairpin RNA (shRNA) and negative control shRNA lentiviruses were used for cell transfection. Reverse transcription‑quantitative polymerase chain reaction and western blotting were employed to verify the role of Nrf2 in SFN‑induced UGT1A. HT‑29 and SW480 cells were divided into a control, an SFN and a PD98059 [an extracellular signal‑regulated kinase (ERK) inhibitor] + SFN group. Western blotting detected the protein levels of Nrf2 and UGT1A. Intracellular levels of reactive oxygen species (ROS) were detected using a reactive oxygen assay kit. The results revealed that SFN inhibits cell proliferation and colony formation, promotes apoptosis, and reduces the migratory ability of CRC cells. The phosphorylation of ERK induced by SFN promoted Nrf2 accumulation. Furthermore, a significant increase in the levels of UGT1A was observed, which coincided with SFN‑induced upregulation of Nrf2 levels in nuclear fractions. Pretreatment with PD58059 reversed the SFN‑induced subcellular translocation of Nrf2 and the expression of UGT1A. In addition, SFN‑induced high levels of ROS in CRC cells may be associated with the ERK signaling pathway. Collectively, these results indicated that SFN inhibited the proliferation of CRC cells and upregulated the expression of UGT1A in CRC cells via the ERK/Nrf2 signaling pathway.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, Lund JL, Pasricha S, Runge T, et al: Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 149:1731–1741.3. 2015. View Article : Google Scholar : PubMed/NCBI
3	Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, et al: Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 68:31–54. 2018. View Article : Google Scholar : PubMed/NCBI
4	Wilson LF, Antonsson A, Green AC, Jordan SJ, Kendall BJ, Nagle CM, Neale RE, Olsen CM, Webb PM and Whiteman DC: How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. Int J Cancer. 142:691–701. 2018. View Article : Google Scholar : PubMed/NCBI
5	Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, Deas A, Elliss-Brookes L, Gavin A, Hounsome L, et al: The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 118:1130–1141. 2018. View Article : Google Scholar : PubMed/NCBI
6	O'Keefe SJ: Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol. 13:691–706. 2016. View Article : Google Scholar : PubMed/NCBI
7	Turner ND and Lloyd SK: Association between red meat consumption and colon cancer: A systematic review of experimental results. Exp Biol Med (Maywood). 242:813–839. 2017. View Article : Google Scholar : PubMed/NCBI
8	Diallo A, Deschasaux M, Latino-Martel P, Hercberg S, Galan P, Fassier P, Allès B, Guéraud F, Pierre FH and Touvier M: Red and processed meat intake and cancer risk: Results from the prospective NutriNet-Sante cohort study. Int J Cancer. 142:230–237. 2018. View Article : Google Scholar : PubMed/NCBI
9	Klusek J, Nasierowska-Guttmejer A, Kowalik A, Wawrzycka I, Chrapek M, Lewitowicz P, Radowicz-Chil A, Klusek J and Głuszek S: The influence of red meat on colorectal cancer occurrence is dependent on the genetic polymorphisms of s-glutathione transferase genes. Nutrients. 11(pii): E16822019. View Article : Google Scholar : PubMed/NCBI
10	Demeyer D, Mertens B, De Smet S and Ulens M: Mechanisms linking colorectal cancer to the consumption of (processed) red meat: A review. Crit Rev Food Sci Nutr. 56:2747–2766. 2016. View Article : Google Scholar : PubMed/NCBI
11	Abid Z, Cross AJ and Sinha R: Meat, dairy, and cancer. Am J Clin Nutr. 100 (Suppl 1):386S–393S. 2014. View Article : Google Scholar : PubMed/NCBI
12	Etemadi A, Abnet CC, Graubard BI, Beane-Freeman L, Freedman ND, Liao L, Dawsey SM and Sinha R: Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: Findings from three large US cohorts. Int J Cancer. 143:2261–2270. 2018. View Article : Google Scholar : PubMed/NCBI
13	Cai T, Yao L and Turesky RJ: Bioactivation of heterocyclic aromatic Amines by UDP glucuronosyltransferases. Chem Res Toxicol. 29:879–891. 2016. View Article : Google Scholar : PubMed/NCBI
14	van der Logt EM, Bergevoet SM, Roelofs HM, van Hooijdonk Z, te Morsche RH, Wobbes T, de Kok JB, Nagengast FM and Peters WH: Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis. 25:2407–2415. 2004. View Article : Google Scholar : PubMed/NCBI
15	Liu M, Wang Q, Liu F, Cheng X, Wu X, Wang H, Wu M, Ma Y, Wang G and Hao H: UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells. PLoS One. 8:e791722013. View Article : Google Scholar : PubMed/NCBI
16	Wang M, Qi YY, Chen S, Sun DF, Wang S, Chen J, Li YQ, Han W and Yang XY: Expression of UDP-glucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue. Oncol Lett. 4:925–930. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yin TF, Wang M, Qing Y, Lin YM and Wu D: Research progress on chemopreventive effects of phytochemicals on colorectal cancer and their mechanisms. World J Gastroenterol. 22:7058–7068. 2016. View Article : Google Scholar : PubMed/NCBI
18	Vuong LD, Nguyen QN and Truong VL: Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells. Immunopharmacol Immunotoxicol. 41:413–419. 2019. View Article : Google Scholar : PubMed/NCBI
19	Mazarakis N, Snibson K, Licciardi PV and Karagiannis TC: The potential use of l-sulforaphane for the treatment of chronic inflammatory diseases: A review of the clinical evidence. Clin Nutr. Mar 25–2019.(Epub ahead of print). PubMed/NCBI
20	Wang M, Chen S, Wang S, Sun D, Chen J, Li Y, Han W, Yang X and Gao HQ: Effects of phytochemicals sulforaphane on uridine diphosphate-glucuronosyltransferase expression as well as cell-cycle arrest and apoptosis in human colon cancer Caco-2 cells. Chin J Physiol. 55:134–144. 2012.PubMed/NCBI
21	Wakabayashi N, Slocum SL, Skoko JJ, Shin S and Kensler TW: When NRF2 talks, who's listening? Antioxid Redox Signal. 13:1649–1663. 2010. View Article : Google Scholar : PubMed/NCBI
22	Thangapandiyan S, Ramesh M, Miltonprabu S, Hema T, Jothi GB and Nandhini V: Sulforaphane potentially attenuates arsenic-induced nephrotoxicity via the PI3K/Akt/Nrf2 pathway in albino Wistar rats. Environ Sci Pollut Res Int. 26:12247–12263. 2019. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Kalthoff S and Strassburg CP: Contribution of human UDP-glucuronosyltransferases to the antioxidant effects of propolis, artichoke and silymarin. Phytomedicine. 56:35–39. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ewa B and Danuta MS: Polycyclic aromatic hydrocarbons and PAH-related DNA adducts. J Appl Genet. 58:321–330. 2017. View Article : Google Scholar : PubMed/NCBI
26	Yang L, Palliyaguru DL and Kensler TW: Frugal chemoprevention: Targeting Nrf2 with foods rich in sulforaphane. Semin Oncol. 43:146–153. 2016. View Article : Google Scholar : PubMed/NCBI
27	Lubelska K, Wiktorska K, Mielczarek L, Milczarek M, Zbroińska-Bregisz I and Chilmonczyk Z: Sulforaphane regulates NFE2L2/Nrf2-dependent xenobiotic metabolism phase ii and phase iii enzymes differently in human colorectal cancer and untransformed epithelial colon cells. Nutri Cancer. 68:1338–1348. 2016. View Article : Google Scholar
28	Vissenaekens H, Grootaert C, Rajkovic A, Van De Wiele T and Calatayud M: The response of five intestinal cell lines to anoxic conditions in vitro. Biol Cell. 111:232–244. 2019. View Article : Google Scholar : PubMed/NCBI
29	Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, et al: Multi-omics of 34 colorectal cancer cell lines-a resource for biomedical studies. Mol Cancer. 16:1162017. View Article : Google Scholar : PubMed/NCBI
30	Cagnol S and Chambard JC: ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J. 277:2–21. 2010. View Article : Google Scholar : PubMed/NCBI
31	Jo C, Kim S, Cho SJ, Choi KJ, Yun SM, Koh YH, Johnson GV and Park SI: Sulforaphane induces autophagy through ERK activation in neuronal cells. FEBS Lett. 588:3081–3088. 2014. View Article : Google Scholar : PubMed/NCBI
32	Wong SY, Tan MG, Wong PT, Herr DR and Lai MK: Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK. J Neuroinflammation. 13:2512016. View Article : Google Scholar : PubMed/NCBI
33	Bucolo C, Drago F, Maisto R, Romano GL, D'Agata V, Maugeri G and Giunta S: Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2-mediated activation of the Nrf2/HO-1 pathway. J Cell Physiol. 234:17295–17304. 2019. View Article : Google Scholar : PubMed/NCBI
34	Svehlikova V, Wang S, Jakubikova J, Williamson G, Mithen R and Bao Y: Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis. 25:1629–1637. 2004. View Article : Google Scholar : PubMed/NCBI
35	Thangapandiyan S, Ramesh M, Hema T, Miltonprabu S, Uddin MS, Nandhini V and Bavithra Jothi G: Sulforaphane potentially ameliorates arsenic induced hepatotoxicity in albino wistar rats: Implication of PI3K/Akt/Nrf2 signaling pathway. Cell Physiol Biochem. 52:1203–1222. 2019. View Article : Google Scholar : PubMed/NCBI
36	Jo GH, Kim GY, Kim WJ, Park KY and Choi YH: Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: The involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway. Int J Oncol. 45:1497–1506. 2014. View Article : Google Scholar : PubMed/NCBI
37	Xin Y, Bai Y, Jiang X, Zhou S, Wang Y, Wintergerst KA, Cui T, Ji H, Tan Y and Cai L: Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway. Redox Biol. 15:405–417. 2018. View Article : Google Scholar : PubMed/NCBI
38	Chikara S, Nagaprashantha LD, Singhal J, Horne D, Awasthi S and Singhal SS: Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment. Cancer Lett. 413:122–134. 2018. View Article : Google Scholar : PubMed/NCBI
39	Miao Z, Yu F, Ren Y and Yang J: D,L-Sulforaphane induces ROS-dependent apoptosis in human gliomablastoma cells by inactivating STAT3 signaling pathway. Int J Mol Sci. 18(pii): E722017. View Article : Google Scholar : PubMed/NCBI
40	Subramani R, Gonzalez E, Arumugam A, Nandy S, Gonzalez V, Medel J, Camacho F, Ortega A, Bonkoungou S, Narayan M, et al: Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci Rep. 6:198192016. View Article : Google Scholar : PubMed/NCBI
41	Pocasap P, Weerapreeyakul N and Thumanu K: Alyssin and iberin in cruciferous vegetables exert anticancer activity in HepG2 by increasing intracellular reactive oxygen species and tubulin depolymerization. Biomol Ther (Seoul). 27:540–552. 2019. View Article : Google Scholar : PubMed/NCBI
42	Jin CY, Molagoda IMN, Karunarathne WAHM, Kang SH, Park C, Kim GY and Choi YH: TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells. Toxicol Appl Pharmacol. 352:132–141. 2018. View Article : Google Scholar : PubMed/NCBI
43	Okonkwo A, Mitra J, Johnson GS, Li L, Dashwood WM, Hegde ML, Yue C, Dashwood RH and Rajendran P: Heterocyclic analogs of sulforaphane trigger DNA damage and impede DNA repair in colon cancer cells: Interplay of HATs and HDACs. Mol Nutr Food Res. 62:e18002282018. View Article : Google Scholar : PubMed/NCBI
44	Chen L, Chan LS, Lung HL, Yip TTC, Ngan RKC, Wong JWC, Lo KW, Ng WT, Lee AWM, Tsao GSW, et al: Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. Phytomedicine. 63:1530582019. View Article : Google Scholar : PubMed/NCBI
45	Erzinger MM, Bovet C, Hecht KM, Senger S, Winiker P, Sobotzki N, Cristea S, Beerenwinkel N, Shay JW, Marra G, et al: Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A. PLoS One. 11:e01502192016. View Article : Google Scholar : PubMed/NCBI
46	Erzinger MM and Sturla SJ: Bioreduction-mediated food-drug interactions: Opportunities for oncology nutrition. Chimia (Aarau). 65:411–415. 2011. View Article : Google Scholar : PubMed/NCBI
47	Milczarek M, Mielczarek L, Lubelska K, Dąbrowska A, Chilmonczyk Z, Matosiuk D and Wiktorska K: In vitro evaluation of sulforaphane and a natural analog as potent inducers of 5-fluorouracil anticancer activity. Molecules. 23(pii): E30402018. View Article : Google Scholar : PubMed/NCBI